Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Sutro Biopharma Inc
F:S090
Sutro Biopharma Inc
F:S090
Price:
11.5
EUR
Market Cap:
€98m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Sutro Biopharma Inc
F:S090
|
US |
|
Vireo Growth Inc
OTC:VREOF
|
US |
|
N
|
Nishi-Nippon Railroad Co Ltd
F:NNR
|
JP |
|
C
|
Coloray International Investment Co Ltd
KOSDAQ:900310
|
HK |
|
Cohort PLC
OTC:COHTF
|
UK |
|
Briscoe Group Ltd
NZX:BGP
|
NZ |
|
P
|
Petronor E&P ASA
OSE:PNOR
|
NO |
|
Vinci SA
PAR:DG
|
FR |
Wall St Price Targets
S090 Price Forecast
Based on 15 analysts
Based on 15 analysts
+413% Upside
from
€11.5
today
Sutro Biopharma Inc (S090)’s 12-month stock price forecast through November 2027 has a consensus target of €59, implying 413% upside. The forecast is based on price targets from 15 Wall Street analysts.
S090 Analyst Rating
No ratings yet
No ratings yet
Sutro Biopharma Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S090's stock price target?
Price Target
59
EUR
59
EUR
According to Wall Street analysts, the average 1-year price target for S090 is 59 EUR with a low forecast of 11.69 EUR and a high forecast of 74.1 EUR.
What is the Revenue forecast for Sutro Biopharma Inc?
Projected CAGR
20%
20%
Over the last 8 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 20%.
